143 related articles for article (PubMed ID: 11888927)
1. Aberrant splicing in several human tumors in the tumor suppressor genes neurofibromatosis type 1, neurofibromatosis type 2, and tuberous sclerosis 2.
Kaufmann D; Leistner W; Kruse P; Kenner O; Hoffmeyer S; Hein C; Vogel W; Messiaen L; Bartelt B
Cancer Res; 2002 Mar; 62(5):1503-9. PubMed ID: 11888927
[TBL] [Abstract][Full Text] [Related]
2. CD44 expression is aberrant in benign Schwann cell tumors possessing mutations in the neurofibromatosis type 2, but not type 1, gene.
Sherman L; Jacoby LB; Lampe J; Pelton P; Aguzzi A; Herrlich P; Ponta H
Cancer Res; 1997 Nov; 57(21):4889-97. PubMed ID: 9354454
[TBL] [Abstract][Full Text] [Related]
3. Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 5' splice-site disruption.
Wimmer K; Roca X; Beiglböck H; Callens T; Etzler J; Rao AR; Krainer AR; Fonatsch C; Messiaen L
Hum Mutat; 2007 Jun; 28(6):599-612. PubMed ID: 17311297
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the rat neurofibromatosis 2 gene and its involvement in asbestos-induced mesothelioma.
Kleymenova EV; Bianchi AA; Kley N; Pylev LN; Walker CL
Mol Carcinog; 1997 Jan; 18(1):54-60. PubMed ID: 9022813
[TBL] [Abstract][Full Text] [Related]
5. A novel mutation in the neurofibromatosis type 1 (NF1) gene promotes skipping of two exons by preventing exon definition.
Fang LJ; Simard MJ; Vidaud D; Assouline B; Lemieux B; Vidaud M; Chabot B; Thirion JP
J Mol Biol; 2001 Apr; 307(5):1261-70. PubMed ID: 11292340
[TBL] [Abstract][Full Text] [Related]
6. Three novel mutations of the NF1 gene detected by temperature gradient gel electrophoresis of exons 5 and 8.
Horn D; Robinson PN; Böddrich A; Buske A; Tinschert S; Nürnberg P
Electrophoresis; 1996 Oct; 17(10):1559-63. PubMed ID: 8957181
[TBL] [Abstract][Full Text] [Related]
7. Functional analysis of splicing mutations in exon 7 of NF1 gene.
Bottillo I; De Luca A; Schirinzi A; Guida V; Torrente I; Calvieri S; Gervasini C; Larizza L; Pizzuti A; Dallapiccola B
BMC Med Genet; 2007 Feb; 8():4. PubMed ID: 17295913
[TBL] [Abstract][Full Text] [Related]
8. RT-PCR splicing analysis of the NF1 open reading frame.
Thomson SA; Wallace MR
Hum Genet; 2002 May; 110(5):495-502. PubMed ID: 12073021
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene.
Kluwe L; MacCollin M; Tatagiba M; Thomas S; Hazim W; Haase W; Mautner VF
Am J Med Genet; 1998 May; 77(3):228-33. PubMed ID: 9605590
[TBL] [Abstract][Full Text] [Related]
10. Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations.
Pros E; Fernández-Rodríguez J; Canet B; Benito L; Sánchez A; Benavides A; Ramos FJ; López-Ariztegui MA; Capellá G; Blanco I; Serra E; Lázaro C
Hum Mutat; 2009 Mar; 30(3):454-62. PubMed ID: 19241459
[TBL] [Abstract][Full Text] [Related]
11. Alterations of pre-mRNA splicing in cancer.
Kalnina Z; Zayakin P; Silina K; Linē A
Genes Chromosomes Cancer; 2005 Apr; 42(4):342-57. PubMed ID: 15648050
[TBL] [Abstract][Full Text] [Related]
12. Frequency and distribution of NF2 mutations in schwannomas.
Jacoby LB; MacCollin M; Barone R; Ramesh V; Gusella JF
Genes Chromosomes Cancer; 1996 Sep; 17(1):45-55. PubMed ID: 8889506
[TBL] [Abstract][Full Text] [Related]
13. The effect of disease-associated HRPT2 mutations on splicing.
Hahn MA; McDonnell J; Marsh DJ
J Endocrinol; 2009 Jun; 201(3):387-96. PubMed ID: 19332451
[TBL] [Abstract][Full Text] [Related]
14. Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients.
Kinoshita K; Hirota S; Isozaki K; Ohashi A; Nishida T; Kitamura Y; Shinomura Y; Matsuzawa Y
J Pathol; 2004 Jan; 202(1):80-5. PubMed ID: 14694524
[TBL] [Abstract][Full Text] [Related]
15. The cytochrome P450 aromatase lacking exon 5 is associated with a phenotype of nonclassic aromatase deficiency and is also present in normal human steroidogenic tissues.
Pepe CM; Saraco NI; Baquedano MS; Guercio G; Vaiani E; Marino R; Pandey AV; Flück CE; Rivarola MA; Belgorosky A
Clin Endocrinol (Oxf); 2007 Nov; 67(5):698-705. PubMed ID: 17608756
[TBL] [Abstract][Full Text] [Related]
16. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH
Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976
[TBL] [Abstract][Full Text] [Related]
17. Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines.
Andersen LB; Fountain JW; Gutmann DH; Tarlé SA; Glover TW; Dracopoli NC; Housman DE; Collins FS
Nat Genet; 1993 Feb; 3(2):118-21. PubMed ID: 8499944
[TBL] [Abstract][Full Text] [Related]
18. Tumor suppressor genes as negative growth regulators in development and differentiation.
Gutmann DH
Int J Dev Biol; 1995 Dec; 39(6):895-908. PubMed ID: 8901192
[TBL] [Abstract][Full Text] [Related]
19. Screening for large mutations of the NF2 gene.
Kluwe L; Nygren AO; Errami A; Heinrich B; Matthies C; Tatagiba M; Mautner V
Genes Chromosomes Cancer; 2005 Apr; 42(4):384-91. PubMed ID: 15645494
[TBL] [Abstract][Full Text] [Related]
20. Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma.
Nunes F; Shen Y; Niida Y; Beauchamp R; Stemmer-Rachamimov AO; Ramesh V; Gusella J; MacCollin M
Cancer Genet Cytogenet; 2005 Oct; 162(2):135-9. PubMed ID: 16213361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
